Dangerous Diabetes Drug- Consumer Protection
Ronald Grisanti D.C., D.A.B.C.O., D.A.C.B.N., M.S.
What do you do when one of the more recent diabetes drugs has the common "black box" warning?
The drug I am referring too isÂ Avandia® (orÂ generic rosiglitazone).
What does it tell you when theÂ mostÂ prestigious and high profile medical journal, New England Journal of Medicine, clearly states that theÂ diabetes drug AvandiaÂ increases the heart attackÂ rate a devastating 43%.
What does it tell you when you see plastered all over television attorneys placing huge ads for those injured byÂ the drug?
What is even more worrisome is even though there are over 700 lawsuitsÂ from people injured by Avandia, totaling more than $60Â million, and even though the human study trials on itÂ had to be ended because it was so dangerous, theÂ FDA was still deciding its fate as of spring 2011.
Would it be pushing the envelope to say that profits may in fact over-rule the protection of the public?
DoesÂ that have anything to do with the fact that it brings inÂ over $3 billion in a year.
In fact studies have shown that notÂ only did Avandia triple the death rate over placeboÂ but it increased congestive heart failure and raisedÂ the bad cholesterol, LDL, 18%.
JustÂ how many millions of dollars, thousands of harmed peopleÂ and hundreds of doctors does it take to prove thatÂ diabetes is not a deficiency of the latest drug?
For many of you reading this short consumer protection update, I simply make it a point to report things as they are.
The goal is to help each and every one of my readers to become better health care consumers and to be extremely knowledgeable on seeking to identify what in fact may be at the root of their health issues.
You really need to have a heart to heart talk with yourself and ask if you simply want to settle with the one size fits all drug approach or would you rather seek the expertise of a physician who seeks to find the underlying root cause of a disease.
That is the power of functional medicine and that power comes from doing a thorough clinical investigation in what are the issues that have led to the disease in the first place.
Nissen SE, et al, Effect of rosiglitazone on the risk of myocardial infarctionÂ and death from cardiovascular causes [published correction appears in NewÂ Engl J Med, 2007; 357 (1): 100] New Engl J Med 356; 24:2457-71, 2007
Mitka M, Critics press FDA to act on evidence of rosiglitazone's cardiacÂ safety issues, J Am Med Assoc, 303;23:2341-2, 2010
Nissen SE, Setting the RECORD straight, J Am Med Assoc, 303; 12:1194-1195, 2010
The information on this website is not intended to replace a one-on-one relationship with a qualified health care professional and is not intended as medical advice. It is intended as a sharing of knowledge and information from the research and experience of Dr. Grisanti and his community. Dr. Grisanti encourages you to make your own health care decisions based upon your research and in partnership with a qualified health care professional. Visit www.FunctionalMedicineUniversity.com to find practitioners thoroughly trained in functional medicine. Look for practitioners who have successfully completed theÂ Functional Medicine University's Certification Program (CFMP).
This content may be copied in full, with copyright, contact, creation and information intact, without specific permission, when used only in a not-for-profit format. If any other use is desired, permission in writing from Dr. Grisanti is required.